Last updated: 09/25/2019 09:40:15

Immunization study to determine the reactogenicity and immunogenicity of Influsplit SSW® 2001/2002 (preservative-free) in persons as of 18 years of age.

GSK study ID
218352/048
Clinicaltrials.gov ID
Not applicable
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Overview
Eligibility
Locations
Study documents
Results summary
Plain language summaries
Additional information

Trial overview

Official title: Immunization study to determine the reactogenicity and immunogenicity of Influsplit SSW® 2001/2002 (preservative-free) in persons as of 18 years of age.
Trial description: Immunization study to determine the reactogenicity and immunogenicity of Influsplit SSW® 2001/2002 (preservative-free) in persons as of 18 years of age.
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:
Not applicable
Secondary outcomes:
Not applicable
Interventions:
Not applicable
Enrollment:
Not applicable
Primary completion date:
Not applicable
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Not applicable
Medical condition
Influenza
Product
Influenza Vaccine (Split Virion, Inactivated)
Collaborators
Not applicable
Study date(s)
N/A to August 2001
Type
Interventional
Phase
3

Participation criteria

Sex
Not applicable
Age
Not applicable
Accepts healthy volunteers
Not applicable

Trial location(s)

This study does not involve prospective enrollment of participants.

Study documents

Scientific result summary
Available language(s): English
Clinical study report
Available language(s): English

If you wish to request for full study report, please contact - [email protected]

Results overview

Refer to study documents

Recruitment status
Study complete
Actual primary completion date
Not applicable
Actual study completion date
2001-20-08

Plain language summaries

Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.

Additional information about the trial

Additional information
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website